Acoramidis in ATTR-CM: Early eGFR Decline Linked With Better Outcomes - Oct 16, 2026 - "To determine whether early eGFR decline during acoramidis therapy correlates with lower risks of recurrent cardiovascular events or all-cause mortality, a team of investigators led by Prem Soman, MD, from the University of Pittsburgh Medical Center conducted a post hoc analysis of the phase 3 ATTRibute-CM trial (NCT03860935). The original double-blind, placebo-controlled study evaluated the safety and efficacy of acoramidis in 632 patients with symptomatic ATTR-CM."
Online posting
|